Scopus BioPharma

Scopus Biopharma, Inc. is a biopharmaceutical company, which engages in the development of transformational therapeutics targeting serious diseases with unmet medical needs. Its drug candidates consist of a combination of cannabidiol-mediated, opioid-sparing anesthetics, synthesis of cannabinoids, and cannabinoid receptor mediating compounds for the treatment of systemic sclerosis. The company was founded on April 18, 2017 and is headquartered in New York, NY.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Scopus Biopharma, Inc. is a biopharmaceutical company, which engages in the development of therapeutics targeting diseases with unmet medical needs. The company was founded on April 18, 2017 and is headquartered in New York, NY.

Duet Therapeutics Integrates Immunotherapy Assets of Scopus and Olimmune, Acquired by Scopus in June 2021

Scopus BioPharma Launches Duet Therapeutics

Alto Ingredients

Cocrystal Pharma

Eyenovia

Hall of Fame Resort & Entertainment

5 Penny Stocks Insiders Are Buying Right Now The post 5 Best Penny Stocks To Buy Right Now According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Best Penny Stocks To Buy Right Now According To Insiders

NEW YORK, July 12, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical needs, today announced a new management appointment following its acquisition of Olimmune Inc., a leading immunotherapy company. Alan Horsager, Ph.D., President and Chief Executive of Olimmune, was appointed President of Scopus with responsibility for overseeing the development of the Company's rapidly expanding immuno-oncology pipeline.

Scopus BioPharma Announces New Management Appointment Following Acquisition of Leading Immunotherapy Company

Transaction Creates Global Leader in Oligonucleotide Cancer Therapeutics

Scopus BioPharma Expands Immunotherapy Pipeline with Acquisition of Olimmune

NEW YORK, May 31, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”) today announced that the board of directors has rescheduled the company's 2021 Annual Meeting of Stockholders (“2021 Annual Meeting”), which will be held on October 8, 2021.

Scopus BioPharma Announces New Date for 2021 Annual Meeting of Stockholders

NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”) today announced it will be rescheduling the company's 2021 Annual Meeting of Shareholders (the “2021 Annual Meeting”), which was previously scheduled for July 16, 2021. Once determined by the Scopus Board of Directors, the company will announce the new date, time and location of the 2021 Annual Meeting.

Scopus BioPharma to Reschedule 2021 Annual Meeting of Shareholders

Joint

SemiLEDs

Moxian BVI

Taiwan Liposome Company Ltd - ADR

These are 5 of the best stock gainers this past week that you should know about: SCPS, TLC, LEDS, JYNT, MOXC. The post 5 Stock Gainers This Past Week: SCPS, TLC, LEDS, JYNT, MOXC appeared first on Pulse 2.0.

5 Stock Gainers This Past Week: SCPS, TLC, LEDS, JYNT, MOXC

The stock price of Scopus BioPharma Inc. (NASDAQ: SCPS) increased by 71.98% yesterday. This is why it happened.

SCPS Stock Price: 71.98% Increase Explanation

Scopus BioPharma (NASDAQ:SCPS) shares are trading higher after the company announced the FDA has approved its IND application for CpG-STAT3siRNA, the company's distinctive immuno-oncology RNA therapy for the treatment of multiple cancers. Scopus BioPharma's stock has been rising Monday, up 102.07% to a price of $11.6.

Why Scopus BioPharma's Stock Is Surging Today

Today, investors in SCPS stock are seeing their investment more than double on a key announcement of an FDA approval for a core therapy. The post SCPS Stock: The Huge FDA News Sending Scopus BioPharma Up 100% appeared first on InvestorPlace.

SCPS Stock: The Huge FDA News Sending Scopus BioPharma Up 100%

Ngm Biopharmaceuticals Inc

Scopus BioPharma Inc. (NASDAQ: SCPS), NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) and Taiwan Liposome Company, Ltd. (NASDAQ: TLC) are among the biggest biopharma movers Monday.

Why Scopus, NGM Biopharma and Taiwan Liposome Are Moving Today

The FDA has signed off investigational new drug application of Scopus BioPharma Inc's (NASDAQ: SCPS) for CpG-STAT3siRNA, the company's distinctive immuno-oncology RNA therapy for the treatment of multiple cancers. A Phase 1 clinical trial for B-cell non-Hodgkin lymphoma will be initiated at the City of Hope.

Why Scopus BioPharma Stock More Than Double Today?

Why Did Scopus BioPharma's Stock More Than Double Today?

Scopus BioPharma Inc. (NASDAQ: SCPS) said the U.S. Food and Drug Administration FDA approved its IND (investigational new drug) application on Monday for CpG-STAT3siRNA – its distinctive immuno-oncology RNA therapy that targets multiple types of cancers. Impact on the share price Following the announcement, Scopus BioPharma jumped roughly 200% in the stock market on Monday […] The post Here's why Scopus BioPharma gained 200% on Monday appeared first on Invezz.

Here's why Scopus BioPharma gained 200% on Monday

GT Biopharma Inc

Sesen Bio Inc.

These biotech penny stocks and former stocks under $5 are turning heads in the analyst community right now The post 3 Biotech Penny Stocks To Watch That Analysts Are Bullish On Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Biotech Penny Stocks To Watch That Analysts Are Bullish On Today

The stock price of Scopus BioPharma Inc. (SCPS) increased by over 200% during intraday trading this morning. This is why it happened.

SCPS Stock Price: Over 200% Increase Explanation

CpG-STAT3siRNA is a Distinctive RNA Therapy and Immunotherapy Developed at City of Hope

Scopus BioPharma Announces FDA Approval of IND Application for Lead Drug Candidate

NEW YORK, April 26, 2021 /PRNewswire/ -- Scopus BioPharma Inc. (Nasdaq: "SCPS") today announced the submission of an investigational new drug application ("IND") to the United States Food and Drug Administration ("FDA") for its immuno-oncology RNA therapy for the treatment of multiple cancers. The IND filing is a key milestone for the planned Phase 1 clinical trial for B-cell non-Hodgkin lymphoma to be initiated at City of Hope.

Scopus BioPharma Announces IND Submission to FDA for Lead Drug Candidate

NEW YORK, March 15, 2021 /PRNewswire/ -- Scopus BioPharma Inc. (Nasdaq: "SCPS") today announced the finalization of arrangements for the completion of the investigational new drug ("IND") package for the company's lead drug candidate and its submission to the United States Food and Drug Administration ("FDA"). The IND submission is expected in Q2 2021.

Scopus BioPharma Finalizes Arrangements for Submission of IND Package

NEW YORK, Feb. 10, 2021 /PRNewswire/ -- Scopus BioPharma Inc. (Nasdaq: SCPS) today announced the closing of the underwriters' over-allotment option in full, bringing total follow-on public offering proceeds to $10.35 million. Scopus is a biopharmaceutical company developing...

Scopus BioPharma Announces Closing of Underwriters' Over-Allotment Option in Full

NEW YORK, Feb. 8, 2021 /PRNewswire/ -- Scopus BioPharma Inc. (Nasdaq: SCPS) today announced that the underwriters of the company's follow-on public offering exercised their over-allotment option in full, bringing total proceeds to $10.35 million. The exercise of the over-allotment option...

Underwriters Exercise Over-Allotment Option in Full, Brings Total Follow-On Public Offering Proceeds to $10.35 Million

NEW YORK, Jan. 29, 2021 /PRNewswire/ -- Scopus BioPharma Inc. (Nasdaq: "SCPS") today announced the closing of a $9 million follow-on public offering. The offering consisted of 1,000,000 shares of common stock at a public offering price of $9.00 per share. The company has granted the...

Scopus BioPharma Announces Closing of $9 Million Follow-On Public Offering

NEW YORK, Jan. 27, 2021 /PRNewswire/ -- Scopus BioPharma Inc. (Nasdaq: "SCPS") today announced that it intends to effectuate an exchange offer (the "Exchange") pursuant to which Scopus BioPharma common stock would become exchangeable for units (the "X Units") of the company. The Exchange...

Scopus BioPharma Announces Exchange Offer

NEW YORK, Jan. 26, 2021 /PRNewswire/ -- Scopus BioPharma Inc. (Nasdaq: "SCPS") today announced the pricing of a $9 million follow-on public offering. The offering consists of 1,000,000 shares of common stock at a public offering price of $9.00 per share. The company has granted the...

Scopus BioPharma Announces Pricing of $9 Million Follow-On Public Offering

NEW YORK, Jan. 19, 2021 /PRNewswire/ -- Scopus BioPharma Inc. (Nasdaq: SCPS) today announced the completion of clinical lot manufacturing fulfilling the requirements for the planned Phase 1 clinical trial for non-Hodgkin's lymphoma. This is a key milestone to enable finalization of the...

News for Scopus BioPharma Stock (SCPS)